INmune Bio (INMB) to Release Quarterly Earnings on Monday

INmune Bio (NASDAQ:INMB) will likely be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect INmune Bio to post earnings of ($0.28) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

INmune Bio Stock Performance

Shares of NASDAQ INMB opened at $1.33 on Friday. The stock has a market cap of $35.35 million, a PE ratio of -0.63 and a beta of 0.77. INmune Bio has a fifty-two week low of $1.21 and a fifty-two week high of $11.64. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.74.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $8.00.

Institutional Investors Weigh In On INmune Bio

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in INmune Bio by 1,042.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after purchasing an additional 66,700 shares during the period. State Street Corp grew its stake in shares of INmune Bio by 22.3% during the fourth quarter. State Street Corp now owns 347,259 shares of the company’s stock valued at $542,000 after buying an additional 63,426 shares during the last quarter. Jain Global LLC purchased a new position in shares of INmune Bio in the fourth quarter worth about $66,000. Goldman Sachs Group Inc. lifted its stake in shares of INmune Bio by 269.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock valued at $88,000 after acquiring an additional 41,173 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of INmune Bio by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after acquiring an additional 28,541 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.